GlaxoSmithKline’s Combivir patent application, claiming combination of two essential AIDS drugs – Zidovudine and Lamivudine – has been opposed under section 25 (1) by Delhi-based Non-Government Organization (NGO). Combivir patent application, filed under mail-box provision (section 5 (2)), has been opposed under the provision of pre-grant opposition questioning the validity of combivir patent application on the technical and health grounds. NGO’s objections states that the grant of patent will increase the cost anti-retroviral treatment for many living with HIV/AIDS and also endanger global availability of affordable medicines. Other objection questions the patentability of Combivir under the Patents Act, 1970 stating that it is mere combination of two known drugs.
No comments:
Post a Comment